The purpose of this study was to determine whether breast cancer patients at stage T2N0 with tumor size ≥4 cm and <4 cm.
Method
Patients with T2N0 stage breast cancer diagnosed between 2010 and 2019 were analyzed in 2 groups as <4 cm (T2a) and ≥4 cm (T2b) in the study using the SEER 17 Research Plus database. The patients’ clinicopathological characteristics and oncological outcomes were included. Group comparisons of prognostic factors, overall survival (OS), and cancer-specific survival (CSS) were made.
Results
In this study, which involved 70971 patients, the T2a group had higher 5-year OS rate (87.2 ± .2 vs 80.8 ± .5%) and 5-year CSS rate (93.7 ± .1% vs 89.4 ± .4%) than the T2b group (P < .001). Univariate analysis revealed that the overall risk of death was 1.5 times higher in T2b than T2a (HR: 1.533 [95% CI: 1.450-1.622], P < .001), whereas multivariate analysis demonstrated the risk was 1.4 times higher (HR: 1.384 [95% CI: 1.307-1.466], P < .001). The risk of cancer-specific death was 1.7 times higher in univariate analysis (HR: 1.691 [95% CI: 1.561-1.832], P < .001) and 1.4 times higher in multivariate analysis (HR: 1.420 [95% CI: 1.309-1.541], P < .001).
Conclusion
Overall survival and BCSS rates in stage T2b breast cancer patients are significantly lower than in T2a patients. Tumor size ≥4 cm in breast cancer is a negative predictor of prognosis.
KasangianAAGherardiGBiagioliE, et al.The prognostic role of tumor size in early breast cancer in the era of molecular biology. PLoS One. 2017;12(12):e0189127. PMID: 29211792; PMCID: PMC5718505. doi:10.1371/journal.pone.0189127
2.
ArslanCSahinUKizilarslanogluC, et al.Early stage “T2N0” breast cancer: does it consist two different “T2” stages?Journal of Clinical Oncology. 2013;31(15_suppl):e11595-e11595.
3.
LiuYHeMZuoWJHaoSWangZHShaoZM. Tumor size still impacts prognosis in breast cancer with extensive nodal involvement. Front Oncol. 2021;11:585613. PMID: 33898305; PMCID: PMC8064390. doi:10.3389/fonc.2021.585613
4.
ZhengYZWangXMFanLShaoZM. Breast cancer-specific mortality in small-sized tumor with stage IV breast cancer: a population-based study. Oncologist. 2021;26(2):e241-e250. Epub 2020 Nov 3. PMID: 33075188; PMCID: PMC7873341. doi:10.1002/onco.13567
5.
BulutNAltundagK. Does estrogen receptor determination affect prognosis in early stage breast cancers?Int J Clin Exp Med. 2015;8(11):21454-21459. PMID: 26885091; PMCID: PMC4723936.
6.
SánchezCDomínguezFGalindoH, et al.Survival rates of advanced estrogen-receptor positive breast cancer. Analysis of 211 cases. Rev Med Chil. 2020;148(9):1233-1238. PMID: 33399697. doi:10.4067/S0034-98872020000901233
7.
JohanssonALVTrewinCBFredrikssonIReinertsenKVRussnesHUrsinG. In modern times, how important are breast cancer stage, grade and receptor subtype for survival: a population-based cohort study. Breast Cancer Res. 2021;23(1):17. PMID: 33526044; PMCID: PMC7852363. doi:10.1186/s13058-021-01393-z
8.
LeeSHKimYSHanW, et al.Tumor growth rate of invasive breast cancers during wait times for surgery assessed by ultrasonography. Medicine (Baltimore). 2016;95(37):e4874. PMCID:PMC5402599. PMID: 27631256. doi:10.1097/MD.0000000000004874
9.
MarczykVRRosaDDMaiaALGoemannIM. Overall survival for HER2-positive breast cancer patients in the HER2-targeted era: evidence from a population-based study. Clin Breast Cancer. 2022;22(5):418-423. Epub 2022 Mar 23. PMID: 35430163. doi:10.1016/j.clbc.2022.03.004
10.
RakhaEAEl-SayedMEGreenARLeeAHRobertsonJFEllisIO. Prognostic markers in triple-negative breast cancer. Cancer. 2007;109(1):25-32. PMID: 17146782. doi:10.1002/cncr.22381
11.
YuanNMengMLiuC, et al.Clinical characteristics and prognostic analysis of triple-negative breast cancer patients. Mol Clin Oncol. 2014;2(2):245-251. Epub 2013 Dec 20. PMID: 24649341; PMCID: PMC3917786. doi:10.3892/mco.2013.230
12.
LaiHWKuoSJ, et al.Prognostic significance of triple negative breast cancer at tumor size 1 cm and smaller. Eur J Surg Oncol. 2011;37(1):18-24. Epub 2010 Nov 19. PMID: 21093206. doi:10.1016/j.ejso.2010.10.003
13.
AlankoJTannerMVanninenRAuvinenAIsolaJ. Triple-negative and HER2-positive breast cancers found by mammography screening show excellent prognosis. Breast Cancer Res Treat. 2021 May;187(1):267-274. doi: 10.1007/s10549-020-06060-zEpub 2021 Jan 8. PMID: 33420595; PMCID: PMC8062374.
14.
YangJJuJGuoL, et al.Prediction of HER2-positive breast cancer recurrence and metastasis risk from histopathological images and clinical information via multimodal deep learning. Comput Struct Biotechnol J. 2022;20:333-342. PMID: 35035786; PMCID: PMC8733169. doi:10.1016/j.csbj.2021.12.028
15.
PanHGrayRBraybrookeJ, et al.20-Year risks of breast-cancer recurrence after stopping endocrine therapy at 5 years. N Engl J Med. 2017;377(19):1836-1846. PMID: 29117498; PMCID: PMC5734609. doi:10.1056/NEJMoa1701830
16.
FouadTMKogawaTLiuDD, et al.Overall survival differences between patients with inflammatory and noninflammatory breast cancer presenting with distant metastasis at diagnosis. Breast Cancer Res Treat. 2015;152(2):407-416. Epub 2015 May 29. Erratum in: Breast Cancer Res Treat. 2015 Jul;152(2):417. PMID: 26017070; PMCID: PMC4492876. doi:10.1007/s10549-015-3436-x
17.
FuscoNSajjadiEVenetisK, et al.Low-risk triple-negative breast cancers: clinico-pathological and molecular features. Crit Rev Oncol Hematol. 2022;172:103643. Epub 2022 Feb 22. PMID: 35217131. doi:10.1016/j.critrevonc.2022.103643
18.
SteadLALashTLSobierajJE, et al.Triple-negative breast cancers are increased in black women regardless of age or body mass index. Breast Cancer Res. 2009;11(2):R18. Epub 2009 Mar 25. PMID: 19320967; PMCID: PMC2688946. doi:10.1186/bcr2242
19.
JiFXiaoWKYangCQ, et al.Tumor location of the central and nipple portion is associated with impaired survival for women with breast cancer. Cancer Manag Res. 2019;11:2915-2925. PMID: 31040717; PMCID: PMC6461001. doi:10.2147/CMAR.S186205
20.
ChenKLiuJZhuLSuFSongEJacobsLK. Comparative effectiveness study of breast-conserving surgery and mastectomy in the general population: a NCDB analysis. Oncotarget. 2015;6(37):40127-40140. PMID: 26517676; PMCID: PMC4741884. doi:10.18632/oncotarget.5394
21.
FowbleBBevanAAlvaradoMMeliskoM. Cancer of the Breast. In: HoppeRTPhillipsTLRoachM, eds. Leibel and Phillips Textbook of Radiation Oncology. 3rd ed. Philadelphia, PA: W.B. Saunders; 2010:1215-1323.
22.
KalinskyKBarlowWEGralowJR. 21-Gene Assay to Inform Chemotherapy Benefit in Node-Positive Breast Cancer. N Engl J Med2021;385:2336-2347. doi:10.1056/NEJMoa2108873
23.
BerdunovVMillenSParamoreA, et al.Cost-effectiveness analysis of the oncotype DX breast recurrence score test in node-positive early breast cancer. J Med Econ. 2022;25(1):591-604. PMID: 35416089. doi:10.1080/13696998.2022.2066399
24.
PilewskieMSevilimeduVErogluI, et al.How often do sentinel lymph node biopsy results affect adjuvant therapy decisions among postmenopausal women with early-stage HR+/HER2- breast cancer in the post-RxPONDER era?Ann Surg Oncol. 2022;29(10):6267-6273. Epub 2022 Jul 18. PMID: 35849294; PMCID: PMC10286823. doi:10.1245/s10434-022-12193-w
25.
JasemJFisherCMAminiA, et al.The 21-gene recurrence score assay for node-positive, early-stage breast cancer and impact of RxPONDER trial on chemotherapy decision-making: have clinicians already decided?J Natl Compr Canc Netw. 2017;15(4):494-503. PMID: 28404760. doi:10.6004/jnccn.2017.0049
